Prion. 2009 Apr-Jun;3(2):78-83. Epub 2009 Apr 21.

Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding.

Source

Department of Neuroscience, MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, London, UK. wendy.noble@iop.kcl.ac.uk

Abstract

Many neurodegenerative disorders share common features including the accumulation of aggregated misfolded proteins, neuroinflammation and the induction of apoptosis. While the contributions of each of these individual elements to neuronal death remain unclear, a commonly used antibiotic, minocycline, has been shown to reduce the progression and severity of disease in several models of neurodegeneration by variously downregulating these molecular pathways. Here we discuss the evidence for the potential of minocycline as a broad-specificity therapeutic agent for those neurodegenerative diseases that are characterized by the presence of misfolded proteins.

PMID:: 19458490; [PubMed - indexed for MEDLINE]
PMCID:: PMC2712603

Free PMC Article

Images from this publication.See all images (2) Free text

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

MINOCYCLINE - HSDB

Supplemental Content

Save items

Related citations in PubMed

Review Clinical potential of minocycline for neurodegenerative disorders. [Neurobiol Dis. 2004]
Review Clinical potential of minocycline for neurodegenerative disorders.
Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M. Neurobiol Dis. 2004 Dec; 17(3):359-66.
Review Protein misfolding and neurodegeneration. [Arch Neurol. 2008]
Review Protein misfolding and neurodegeneration.
Soto C, Estrada LD. Arch Neurol. 2008 Feb; 65(2):184-9.
Review Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. [Int Rev Neurobiol. 2007]
Review Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
Lipton SA, Gu Z, Nakamura T. Int Rev Neurobiol. 2007; 82:1-27.
Review Minocycline and neurodegenerative diseases. [Behav Brain Res. 2009]
Review Minocycline and neurodegenerative diseases.
Kim HS, Suh YH. Behav Brain Res. 2009 Jan 23; 196(2):168-79. Epub 2008 Oct 11.
Review Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases. [Curr Pharm Biotechnol. 2010]
Review Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases.
Arawaka S, Machiya Y, Kato T. Curr Pharm Biotechnol. 2010 Feb; 11(2):158-66.

See reviews... See all...

Cited by 3 PubMed Central articles

Anti-inflammatory impact of minocycline in a mouse model of tauopathy. [Front Psychiatry. 2010]
Anti-inflammatory impact of minocycline in a mouse model of tauopathy.
Garwood CJ, Cooper JD, Hanger DP, Noble W. Front Psychiatry. 2010 Oct 12; 1:136. Epub 2010 Oct 12.
Protein quality control in heart disease: using established drugs to target novel mechanisms. [J Am Coll Cardiol. 2010]
Protein quality control in heart disease: using established drugs to target novel mechanisms.
Villarreal F, Lew WY. J Am Coll Cardiol. 2010 Oct 19; 56(17):1427-9.
Review Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. [Brain Struct Funct. 2010]
Review Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
Wisniewski T, Boutajangout A. Brain Struct Funct. 2010 Mar; 214(2-3):201-18. Epub 2009 Dec 10.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Minocycline as a potential therapeutic agent in neurodegenerative disorders char...
Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding.
Prion. 2009 Apr-Jun ;3(2):78-83. Epub 2009 Apr 21 .

PubMed
Worksite policies related to influenza vaccination: a cross-sectional survey of ...
Worksite policies related to influenza vaccination: a cross-sectional survey of US registered nurses.
Hum Vaccin. 2009 Aug ;5(8):545-50. Epub 2009 Aug 21 .

PubMed
Autophagy is required for extension of yeast chronological life span by rapamyci...
Autophagy is required for extension of yeast chronological life span by rapamycin.
Autophagy. 2009 Aug ;5(6):847-9. Epub 2009 Aug 23 .

PubMed
Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exh...
Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis.
J Lipid Res. 2009 Nov ;50(11):2299-305. Epub 2009 May 20 .

PubMed
Preemption and malpractice liability.
Preemption and malpractice liability.
N Engl J Med. 2009 May 21 ;360(21):2257-8; author reply 2258.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: